TrumpRx Web Site

TrumpRx.gov is now up and running:

https://trumprx.gov/

https://www.whitehouse.gov/fact-sheets/2026/02/fact-sheet-president-donald-j-trump-launches-trumprx-gov-to-bring-lower-drug-prices-to-american-patients/

Fact Sheet: President Donald J. Trump Launches TrumpRx.gov to Bring Lower Drug Prices to American Patients
The White House
February 5, 2026

HISTORIC LAUNCH TO LOWER DRUG PRICES FOR AMERICAN PATIENTS: Today, President Donald J. Trump announced the launch of TrumpRx.gov. Through the website, patients will be able to access large discounts on many of the most popular and highest-priced medicines in the country, paying prices in line with the lowest paid by other developed nations (known as the most-favored-nation, or MFN, price).

• Today’s launch features drugs made by the first five manufacturers to reach MFN pricing deals with the Trump Administration: AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer.
• Additional drugs from other companies that have signed MFN pricing deals will be made available through TrumpRx.gov in the coming months.
• TrumpRx.gov provides patients with access to a world-class experience for accessing deep discounts on the medicines they need. Depending on the manufacturer of a given drug, patients with valid prescriptions will be able to access savings through user-friendly coupons that can be printed or downloaded onto their phones or through channels set up by the manufacturer and integrated into TrumpRx.gov.

DELIVERING LOWER COSTS ON THE MOST POPULAR DRUGS: As of today, patients purchasing directly through TrumpRx.gov will be able to see massive price reductions on 40 of the most popular and expensive branded medicines in the nation. Select examples include:

• Historic price reductions for Americans on the two drugs with the highest annual expenditures in the United States, which help adults struggling with diabetes, heart disease (Ozempic and Wegovy only), obesity, and other conditions.
• The monthly prices of Ozempic and injectable Wegovy will fall from $1,028 and $1,349, respectively, to an average price of $350 and as low as $199, depending on dosage strength.The monthly price of the Wegovy pill will fall from $1,349 to as low as $149, depending on dosage strength.
• The monthly price of Zepbound and will fall from $1,088 to an average price of $346 and as low as $299, depending on dosage strength.
• Massive savings on some of the most commonly used fertility medications in the country to help families grow. Many patients struggling with infertility pay for their medicines out-of-pocket, meaning they will stand to save more than $2,000 per cycle of fertility drugs, on average.
• Gonal-F, one of the most commonly-used fertility drugs, will see its price reduced to as low as $168 per pen, depending on dosage strength.
• The price of Cetrotide, another commonly used fertility medicine, will drop from $316 to $22.50.
• The price of Ovidrel will fall from $251 to $84.
• Discounts on numerous other high-cost drugs, including:
• Bevespi Aerosphere, an inhaler used to treat chronic obstructive pulmonary disease (COPD), will be discounted from $458 to $51.
• Airsupra, an inhaler used to treat asthma symptoms and attacks, will see a price drop from $504 to $201.
• Eucrisa, a topical ointment for atopic dermatitis, will be discounted from $792 to $158.
• Insulin Lispro will be available for as low as $25 per month.
• Duavee, a medication used to treat hot flashes and osteoporosis, will see its price cut from $202 to $30.

DELIVERING ON PROMISES TO PUT AMERICAN PATIENTS FIRST: President Trump is delivering on promises to ensure American patients no longer pay high prices to subsidize low prices in the rest of the world, something the political establishment did not believe was possible.

• On May 12, 2025, President Trump signed an Executive Order titled: “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients” directing the Administration to take numerous actions to bring American drug prices in line with those paid by similar nations.
• On July 31, 2025, President Trump sent letters to leading pharmaceutical manufacturers outlining the steps they must take to bring down the prices of prescription drugs in the United States to match the lowest price offered in other developed nations.
• Since September 30, 2025, President Trump has announced 16 deals with major pharmaceutical manufacturers to bring prices in line with those paid in other developed nations, which will provide substantial price relief on numerous products taken by millions of Americans.
• On December 1, 2025, the Office of the United States Trade Representative, the Department of Commerce, and the Department of Health and Human Services announced an agreement with the United Kingdom (U.K.) that will increase the net price of new prescription drugs by 25% in the U.K., helping ensure that they pay their fair share for innovative medicines.
• On January 15, 2026, President Trump called on Congress to enact The Great Healthcare Plan, which would lower drug prices by codifying the savings from his Most-Favored-Nation pricing initiative, lower insurance premiums, hold insurance companies accountable, and maximize price transparency.

Johnson & Johnson will start selling Invokamet, ​Invokamet XR, Invokana, and Xarelto through the TrumpRx ⁠platform:

https://www.reuters.com/business/healthcare-pharmaceuticals/johnson-johnson-launch-trumprx-with-four-its-prescription-drugs-cbs-news-reports-2026-04-24/

Johnson & Johnson to offer four prescription medicines on TrumpRx website
By Padmanabhan Ananthan in Bengaluru - April 24, 2026

April 24 (Reuters) - Johnson & Johnson (JNJ.N) will start selling four of its ​medications on the Trump administration's TrumpRx ‌website, the company told Reuters on Friday.

The company said it would begin offering its diabetes drugs Invokamet, ​Invokamet XR and Invokana, as well ​as blood thinner Xarelto, through the TrumpRx ⁠platform and its direct‑to‑consumer website, JNJ ​Direct.

The healthcare conglomerate voluntarily reached an agreement with ​the Trump administration in January to reduce drug prices for Americans, expanding access to affordable prescriptions under ​Medicaid and marketing its products on ​the TrumpRx platform in exchange for an exemption from ‌the ⁠administration's tariffs.

Other drugmakers including Pfizer (PFE.N), Novo Nordisk (NOVOb.CO), Eli Lilly (LLY.N), and AstraZeneca (AZN.L) have entered into similar deals tied to TrumpRx or so‑called "most‑favoured‑nation" pricing ​aimed at lowering ​U.S. ⁠drug costs and encouraging domestic production.

TrumpRx is meant to serve cash‑paying ​patients with valid prescriptions, including uninsured ​consumers ⁠and those whose insurance does not cover a particular drug.

Johnson & Johnson previously pledged $55 billion ⁠in research ​and production, including facilities ​in Pennsylvania and North Carolina.